• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU

NEUREN PHARMACEUTICALS LIMITED - Charts / Financials

5.76% ! $13.10
Market Cap $1.629B  !
Healthcare Biotechnology
Add to My Watchlist

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

refresh Created with Sketch. REFRESH
Day
Open $13.95   Day High $13.96   Day Low $12.88
Daily Volume 725687
Bids   Sellers
Number Price Volume   Number Price Volume
1 $13.10 266   2 $13.15 1619

Directors & Senior Management

Mr. Jonathan Charles Pilcher Chief Executive Officer, Managing Director, Executive Director
Ms. Lauren Frazer Chief Financial Officer, Company Secretary
Dr. Clive Blower Chief Operating Officer
Mr. Larry Glass Chief Science Officer
Ms. Liza Squires Chief Medical Officer
Mr. Gerry Zhao Chief Business Officer
Mr. Patrick Donald Davies Non-Executive Independent Chairman of the Board
Ms. Dianne Angus Non-Executive Independent Director
Mr. Joseph Basile Non-Executive Independent Director
Dr. Jenny Lee Harry Non-Executive Independent Director

Data source: Refinitiv

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
$13.10 		Change
-0.800(5.76%) 		Mkt cap ! $1.629B
Open High Low Value Volume
$13.95 $13.96 $12.88 $9.534M 725.6K

Buyers (Bids)

No. Vol. Price($)
1 266 $13.10
 

Sellers (Offers)

Price($) Vol. No.
$13.15 1619 2
View Market Depth
Last trade - 16.10pm 13/06/2025 (20 minute delay) ?

Top Stories

Zip's stunning comeback: Is this the start of a $14 revival?

Just when the market had written it off… Zip Co (ASX: ZIP) has come roaring back to life. The Buy Now, Pay Later company stunned investors last Wednesday with a 15% surge in its share price soon after upgrading its full-year earnings forecast to at least $160 million @ up from $153 million...
Iberian expansion: Megado turns to Europe with Spanish copper mines Megado Minerals has added the Iberian Copper Project in Spain to its expanding collection after buying an 80% interest in Iberian Copper.
ASX Ltd notches upward on sale of company meant to fix CHESS 3 years ago ASX Ltd (ASX:ASX) has notched fractional gains in early Friday trades on the news it's ditched its shareholdings in...
Week 24 Wrap: WW3 looms (again); US econ data tepid & silver surfing By and large, I don't think I'd be without peers when I said the biggest thing that happened this week was on energy markets.
Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing) Welcome to this week’s HotCopperWire, our market watch podcast!Each week, HotCopper’s senior markets reporter Jonathon Davidson and I take you through all the week’s biggest news headlines @ and what they mean for Aussie investors.In this Week ...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.